Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
26 sept. 2024 16h01 HE | Travere Therapeutics, Inc.
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 sept. 2024 17h00 HE | Travere Therapeutics, Inc.
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
10 sept. 2024 16h01 HE | Travere Therapeutics, Inc.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on...
FILSPARI (sparsentan)
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
05 sept. 2024 17h34 HE | Travere Therapeutics, Inc.
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
22 août 2024 16h30 HE | Travere Therapeutics, Inc.
Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium.
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at Upcoming Investor Conferences
06 août 2024 16h30 HE | Travere Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 août 2024 16h01 HE | Travere Therapeutics, Inc.
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Report Second Quarter 2024 Financial Results
25 juil. 2024 16h30 HE | Travere Therapeutics, Inc.
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
08 juil. 2024 16h30 HE | Travere Therapeutics, Inc.
Travere Therapeutics management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 juin 2024 17h00 HE | Travere Therapeutics, Inc.
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement...